StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Each row shows where IOVA sits in our scored universe today on a single observational measurement. P85 means IOVA ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-07 | $3.51 | $3.55 | +1.14% | 41.0M |
| 05-08 | $3.52 | $3.62 | +2.84% | 20.7M |
| 05-11 | $3.64 | $3.70 | +1.65% | 19.0M |
| 05-12 | $3.74 | $3.56 | -4.81% | 29.9M |
| 05-13 | $3.56 | $3.66 | +2.81% | 7.9M |
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Each factor shows IOVA's percentile within the scored universe — observational ranking, not a recommendation.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for IOVA.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for IOVA.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
| Metric | Q3 2026 (Est.) Expected 2026-08-05 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $88.11M | $71.43M | $263.50M | $176.73M | $109.28M |
Operating Income | Not available | $-81.04M | $-403.36M | $-329.90M | $-235.00M |
Net Income | Not available | $-79.05M | $-390.98M | $-319.07M | $-227.82M |
EPS (Diluted) | $-0.13 | $-0.19 | $-1.09 | $-0.94 | $-0.69 |
Total Assets | Not available | $925.66M | $913.17M | $904.95M | $907.44M |
Total Liabilities | Not available | $203.91M | $214.59M | $202.66M | $208.95M |
Cash & Equivalents | Not available | $196.51M | $163.08M | $158.13M | $132.47M |
Free Cash Flow OCF − CapEx | Not available | $-78.68M | $-336.24M | $-274.36M | $-184.81M |
Shares Outstanding | Not available | 438.11M | 411.94M | 385.46M | 341.92M |
Press releases, AI summaries, and links to free transcript sources. Audio webcasts live on the issuer's IR site.
Press releases served direct from sec.gov. Stonvex doesn't host transcript bodies — these require the publisher's terms.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
What drives IOVA's price movement
Outperforming its sector. Watch for sector rotation and relative momentum shifts.
Outperforming sector peers — leadership position
Highly momentum-driven — trends tend to persist
Moderate news sensitivity
Moderate sentiment influence
Low flow signal — not institutional-driven
Low volume impact — moves on other factors
DNA analysis is based on current factor scoring. Not investment advice.
Quiet session — no dominant driver
Research only. Labels above describe the current state of the stock using price, volume, and news data — they are not buy or sell recommendations. Stonvex is not a registered investment advisor. Past market behavior does not imply future results.